{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+medium&page=7",
    "query": {
      "intervention": "Control medium",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 723,
    "total_pages": 73,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+medium&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+medium&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T22:02:15.807Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06719219",
      "title": "A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcus (S.) Aureus Infection"
      ],
      "interventions": [
        {
          "name": "LTB-SA7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "LimmaTech Biologics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 129,
      "start_date": "2025-01-07",
      "completion_date": "2026-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06719219"
    },
    {
      "nct_id": "NCT01868334",
      "title": "SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Influenza Vaccinations",
        "Adult PPSV Vaccinations",
        "Adult Tdap/Td Vaccinations"
      ],
      "interventions": [
        {
          "name": "Pillar 1: Convenient Vaccination Services",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pillar 2: Patient notification",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pillar 3: Enhanced Office Systems",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pillar 4: Motivation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70549,
      "start_date": "2013-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868334"
    },
    {
      "nct_id": "NCT05281692",
      "title": "Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Enhanced Preservation Media (EPM-IX)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Convergent Genomics, Inc.",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2022-02-02",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281692"
    },
    {
      "nct_id": "NCT03326336",
      "title": "Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-syndromic Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Gene therapy: GS030-DP AND Medical device: GS030-MD",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-09-26",
      "completion_date": "2027-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326336"
    },
    {
      "nct_id": "NCT03487276",
      "title": "Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa (HS)"
      ],
      "interventions": [
        {
          "name": "IFX-1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InflaRx GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 179,
      "start_date": "2018-02-26",
      "completion_date": "2020-01-27",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Fort Myers, Florida • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        },
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03487276"
    },
    {
      "nct_id": "NCT01588535",
      "title": "Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Otitis Media"
      ],
      "interventions": [
        {
          "name": "benzocaine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbor Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "2 Months to 4 Years"
      },
      "enrollment_count": 38,
      "start_date": "2012-05",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2015-05-04",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 15,
      "location_summary": "Jonesboro, Arkansas • Miami Beach, Florida • West Des Moines, Iowa + 11 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Fremont",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01588535"
    },
    {
      "nct_id": "NCT05084508",
      "title": "A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Investigational varicella vaccine low potency",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational varicella vaccine medium potency",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational varicella vaccine high potency",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed varicella vaccine Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed varicella vaccine Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, mumps, and rubella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13-valent pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 800,
      "start_date": "2022-02-03",
      "completion_date": "2024-06-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 41,
      "location_summary": "Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more",
      "locations": [
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05084508"
    },
    {
      "nct_id": "NCT02074410",
      "title": "Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "OMS643762",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2014-01",
      "completion_date": "2014-10-15",
      "has_results": false,
      "last_update_posted_date": "2018-10-22",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Englewood, Colorado • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02074410"
    },
    {
      "nct_id": "NCT00518713",
      "title": "Clobazam in Patients With Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Epilepsy, Generalized",
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Clobazam Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Clobazam Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "Clobazam High Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundbeck LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "2 Years to 60 Years"
      },
      "enrollment_count": 238,
      "start_date": "2007-08",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-02-09",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 34,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00518713"
    },
    {
      "nct_id": "NCT02580591",
      "title": "Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 977,
      "start_date": "2015-12-22",
      "completion_date": "2017-09-20",
      "has_results": true,
      "last_update_posted_date": "2018-11-02",
      "last_synced_at": "2026-10-17T22:02:15.807Z",
      "location_count": 39,
      "location_summary": "Montgomery, Alabama • Concord, California • Fresno, California + 33 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02580591"
    }
  ]
}